Serum alpha-CGRP levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system.
CGRP
COVID-19
Headache trigeminal system
alpha-CGRP
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
16
09
2022
accepted:
09
03
2023
entrez:
18
3
2023
pubmed:
19
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
Headache is among the most frequent symptoms of acute COVID-19 infection. Its mechanisms remain obscure, but due to its migraine-like characteristics, the activation of the trigeminal system could account for its underlying pathophysiology. Our aim was to compare the serum levels of CGRP, as a theoretical marker of trigemino-vascular activation, in 25 COVID-19 inpatients with lung involvement experiencing headache, against 15 COVID-19 inpatients without headache and with those of 25 matched healthy controls with no headache history. Morning serum alpha-CGRP levels, as measured by ELISA (Abbexa, UK), were increased in COVID-19 patients with headache (55.2±34.3 pg/mL) vs. controls (33.9±14.0 pg/mL) (p < 0.01). Alpha-CGRP levels in COVID-19 patients without headache were also significantly increased (43.3 ± 12.8 pg/mL; p = 0.05) versus healthy controls, but were numerically lower (-28.2%; p = 0.36) as compared to COVID-19 patients with headache. CGRP levels are increased in COVID-19 patients experiencing headache in the acute phase of this disease, which could explain why headache frequently occurs in COVID-19 and strongly supports a role for trigeminal activation in the pathophysiology of headache in this viral infection.
Sections du résumé
BACKGROUND
BACKGROUND
Headache is among the most frequent symptoms of acute COVID-19 infection. Its mechanisms remain obscure, but due to its migraine-like characteristics, the activation of the trigeminal system could account for its underlying pathophysiology.
METHODS
METHODS
Our aim was to compare the serum levels of CGRP, as a theoretical marker of trigemino-vascular activation, in 25 COVID-19 inpatients with lung involvement experiencing headache, against 15 COVID-19 inpatients without headache and with those of 25 matched healthy controls with no headache history.
RESULTS
RESULTS
Morning serum alpha-CGRP levels, as measured by ELISA (Abbexa, UK), were increased in COVID-19 patients with headache (55.2±34.3 pg/mL) vs. controls (33.9±14.0 pg/mL) (p < 0.01). Alpha-CGRP levels in COVID-19 patients without headache were also significantly increased (43.3 ± 12.8 pg/mL; p = 0.05) versus healthy controls, but were numerically lower (-28.2%; p = 0.36) as compared to COVID-19 patients with headache.
CONCLUSION
CONCLUSIONS
CGRP levels are increased in COVID-19 patients experiencing headache in the acute phase of this disease, which could explain why headache frequently occurs in COVID-19 and strongly supports a role for trigeminal activation in the pathophysiology of headache in this viral infection.
Identifiants
pubmed: 36932352
doi: 10.1186/s12883-023-03156-z
pii: 10.1186/s12883-023-03156-z
pmc: PMC10021037
doi:
Substances chimiques
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Subventions
Organisme : Instituto de Investigación Marqués de Valdecilla
ID : INNVAL 20/25
Organisme : Instituto de Salud Carlos III
ID : PI20/01358
Informations de copyright
© 2023. The Author(s).
Références
Ann Neurol. 1990 Aug;28(2):183-7
pubmed: 1699472
Headache. 2018 Jan;58(1):78-87
pubmed: 29131327
Cephalalgia. 2022 Jul;42(8):804-809
pubmed: 35166156
Neurology. 2012 Jul 31;79(5):474-9
pubmed: 22815557
Cephalalgia. 2022 Feb;42(2):176-180
pubmed: 34407648
Arch Med Res. 2023 Jan;54(1):56-63
pubmed: 36588002
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
Cephalalgia. 2022 Mar;42(3):186-196
pubmed: 34601944
Neurology. 2013 Oct 1;81(14):1191-6
pubmed: 23975872
J Headache Pain. 2021 Aug 12;22(1):94
pubmed: 34384355
Cephalalgia. 2021 Apr;41(5):613-630
pubmed: 33291995
Cephalalgia. 2017 Jan;37(1):49-63
pubmed: 26888294
Dig Dis Sci. 2022 Dec;67(12):5712-5713
pubmed: 35305169
Sci Rep. 2021 Jul 19;11(1):14674
pubmed: 34282206
Headache. 2020 Jul;60(7):1450-1452
pubmed: 32386433
Cephalalgia. 2020 Nov;40(13):1410-1421
pubmed: 33146036
Front Pain Res (Lausanne). 2022 Apr 01;3:858709
pubmed: 35434707
J Endocr Soc. 2021 Jan 04;5(3):bvaa199
pubmed: 33506161
Cephalalgia. 2020 Nov;40(13):1443-1451
pubmed: 33146035
Headache. 2020 Jul;60(7):1415-1421
pubmed: 32412101